11 companies

Merck

Market Cap: US$278.8b

Operates as a healthcare company worldwide.

MRK

US$114.62

7D

-0.7%

1Y

43.6%

Illumina

Market Cap: US$19.8b

Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

ILMN

US$125.44

7D

-5.5%

1Y

61.6%

Exelixis

Market Cap: US$11.9b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

EXEL

US$46.05

7D

3.8%

1Y

23.8%

ACADIA Pharmaceuticals

Market Cap: US$3.8b

A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

ACAD

US$22.11

7D

4.0%

1Y

49.1%

ADMA Biologics

Market Cap: US$2.5b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

ADMA

US$11.08

7D

3.2%

1Y

-50.4%

Aurinia Pharmaceuticals

Market Cap: US$2.2b

A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.

AUPH

US$16.14

7D

2.0%

1Y

99.3%

Theravance Biopharma

Market Cap: US$853.2m

A biopharmaceutical company, develops and commercializes medicines in the United States.

TBPH

US$16.31

7D

-2.8%

1Y

71.0%

CorMedix

Market Cap: US$587.4m

A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

CRMD

US$7.33

7D

2.8%

1Y

-19.9%

Abeona Therapeutics

Market Cap: US$320.2m

A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.

ABEO

US$5.52

7D

2.6%

1Y

2.4%

Compugen

Market Cap: US$267.6m

A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.

CGEN

US$2.92

7D

1.0%

1Y

97.3%

Oramed Pharmaceuticals

Market Cap: US$157.7m

Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

ORMP

US$3.84

7D

-0.5%

1Y

67.0%